Clinical, microbiological, and economic benefit of a change in antibiotic prophylaxis for cardiac surgery

Infect Control Hosp Epidemiol. 2002 Jul;23(7):402-4. doi: 10.1086/502074.

Abstract

Vancomycin and rifampicin replaced cephazolin as antibiotic prophylaxis for coronary artery bypass surgery at our institution. Following this intervention, there was a significant decrease (P < .001) in the surgical-site infection rate from 10.5 (95% confidence interval, 8.2 to 13.3) to 4.9 (95% confidence interval, 3.2 to 7.1) infections per 100 procedures. An estimated $576,655 (Australian) was saved between two 12-month periods.

MeSH terms

  • Administration, Oral
  • Anti-Bacterial Agents / administration & dosage
  • Antibiotic Prophylaxis*
  • Coronary Artery Bypass / adverse effects*
  • Coronary Artery Bypass / economics
  • Cost-Benefit Analysis
  • Drug Therapy, Combination / administration & dosage*
  • Female
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Rifampin / administration & dosage*
  • Surgical Wound Infection / economics
  • Surgical Wound Infection / prevention & control*
  • Vancomycin / administration & dosage*

Substances

  • Anti-Bacterial Agents
  • Vancomycin
  • Rifampin